Pharmaceutical Companies

Under the renewed agreement, Bora will provide end-to-end manufacturing services for more than 20 commercial GSK product lines.

Novartis will continue operating its subsidiary Novartis Healthcare Private Limited, which serves as the commercial arm for the company’s operations in India.

The acquisition centers on anitocabtagene autoleucel, known as anito-cel, an investigational CAR-T cell therapy targeting multiple myeloma.

The pharmaceutical giant will pay Frontier USD 40 million upfront, with additional payments of up to USD 963 million tied to achieving specific development, regulatory, and commercial milestones.

The partnership forms a cornerstone of “Plan Mexico,” a government-led economic growth strategy designed to attract investment and develop domestic manufacturing capabilities.

At the heart of this collaboration sits Ribo’s GalSTAR platform, a specialized system designed to help develop RNA interference therapeutics that target disease-causing genes in liver conditions.

The acquisition gives Lilly access to Orna’s innovative platform, which combines circular RNA (circRNA) with lipid nanoparticle-based therapies.

The new San Diego facility will function as a critical node in Novartis’s integrated global research network, connecting seamlessly with existing research hubs in Basel, Switzerland, and Cambridge, Massachusetts.

The partnership centers on incorporating Diagnoly’s Fetoly platform into GE HealthCare’s established Voluson women’s health ultrasound systems, marking a significant advancement in prenatal diagnostic technology.

The partnership merges Fujitsu Japan’s deep knowledge of the medical field and cutting-edge technologies, including artificial intelligence, with JMDC’s sophisticated prediction models derived from insurance user data.